{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:17:48Z","timestamp":1780935468332,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ijantimicag.2020.106128","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T11:17:52Z","timestamp":1596453472000},"page":"106128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany"],"prefix":"10.1016","volume":"56","author":[{"given":"Michael","family":"Kresken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Korte-Berwanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren G.","family":"Gatermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Pfennigwerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106128_bib0001","series-title":"Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis","year":"2017"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0002","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/IDR.S173867","article-title":"Antibiotic resistance: a rundown of a global crisis","volume":"11","author":"Aslam","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0003","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/cc13948","article-title":"The future of antibiotics","volume":"18","author":"Spellberg","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0004","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an inter-national expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0005","series-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","year":"2017"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00093-17","article-title":"In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0007","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/AAC.01695-15","article-title":"In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains","volume":"60","author":"Kohira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0008","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0009","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1128\/AAC.03098-15","article-title":"Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases","volume":"60","author":"Ito-Horiyama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0010","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ijantimicag.2018.11.005","article-title":"Stability of cefiderocol against clinically significant broad-spectrum oxacillinases","volume":"52","author":"Poirel","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0011","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/jac\/dky317","article-title":"Stability and low induction propensity of cefiderocol against chromosomal AmpC \u03b2-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae","volume":"73","author":"Ito","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0012","year":"2006"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0013","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing; twenty-seventh informational supplement. Document M100-S30. Wayne, PA: Clinical and Laboratory Standards Institute; 2020."},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0014","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters, Version 10.0; 2020. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_10.0_Breakpoint_Tables.pdf [accessed 20 March 2020]."},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0015","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/ijerph16091530","article-title":"Extended-Spectrum Beta-Lactamase (ESBL)-Producing Escherichia coli Isolated from Flies in the Urban Center of Berlin, Germany","volume":"16","author":"Wetzker","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0016","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijantimicag.2006.01.004","article-title":"Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp","volume":"27","author":"Woodford","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0017","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1128\/AAC.02413-12","article-title":"OXA-235, a novel class D \u03b2-lactamase involved in resistance to carbapenems in Acinetobacter baumannii","volume":"57","author":"Higgins","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105959","article-title":"Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany","volume":"55","author":"Kresken","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0019","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpubh.2019.00151","article-title":"The \u201cOld\u201d and the \u201cNew\u201d Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How","volume":"7","author":"Karaiskos","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00794-17","article-title":"Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae","volume":"61","author":"Cojutti","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0021","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/AAC.00188-13","article-title":"Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae","volume":"57","author":"Ceccarelli","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0022","article-title":"Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms","volume":"62","author":"Wi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ijantimicag.2020.106128_bib0023","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0024","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.idc.2016.02.011","article-title":"Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases","volume":"30","author":"Doi","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0025","unstructured":"U.S. Food and Drug Administration. Cefiderocol Injection. FDA Identified Interpretive Criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/cefiderocol-injection. Content current as of 20 November 2019 [accessed 24 March 2020]."},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0026","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0027","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0028","first-page":"e01801","article-title":"ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum \u03b2-Lactamases and Carbapenemases","volume":"63","author":"Jacobs","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106128_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:36:57Z","timestamp":1760377017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920303113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0924857920303113"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106128","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106128"}}